CA2715657A1 - Novel polymorphs and processes for their preparation - Google Patents

Novel polymorphs and processes for their preparation Download PDF

Info

Publication number
CA2715657A1
CA2715657A1 CA2715657A CA2715657A CA2715657A1 CA 2715657 A1 CA2715657 A1 CA 2715657A1 CA 2715657 A CA2715657 A CA 2715657A CA 2715657 A CA2715657 A CA 2715657A CA 2715657 A1 CA2715657 A1 CA 2715657A1
Authority
CA
Canada
Prior art keywords
solvent
sunitinib malate
process according
sunitinib
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2715657A
Other languages
English (en)
French (fr)
Inventor
Abhay Gaitonde
Bharati Choudhari
Prakash Bansode
Sunanda Phadtare
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CA2715657A1 publication Critical patent/CA2715657A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CA2715657A 2008-02-21 2009-02-20 Novel polymorphs and processes for their preparation Abandoned CA2715657A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN314/KOL/2008 2008-02-21
IN314KO2008 2008-02-21
PCT/GB2009/050170 WO2009104021A2 (en) 2008-02-21 2009-02-20 Novel polymorphs and processes for their preparation

Publications (1)

Publication Number Publication Date
CA2715657A1 true CA2715657A1 (en) 2009-08-27

Family

ID=40466924

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2715657A Abandoned CA2715657A1 (en) 2008-02-21 2009-02-20 Novel polymorphs and processes for their preparation

Country Status (7)

Country Link
US (1) US20110112164A1 (https=)
EP (1) EP2252607A2 (https=)
JP (1) JP2011512396A (https=)
CN (1) CN101983195A (https=)
AU (1) AU2009215377A1 (https=)
CA (1) CA2715657A1 (https=)
WO (1) WO2009104021A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063777B (en) 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof
WO2010011834A2 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
EP2896618A1 (en) * 2009-01-02 2015-07-22 Hetero Research Foundation Polymorphs of sunitinib malate
CA2774634A1 (en) 2009-09-16 2011-03-24 Ranbaxy Laboratories Limited Salts of sunitinib
EP2499133A2 (en) * 2009-11-12 2012-09-19 Ranbaxy Laboratories Limited Process for the preparation of crystalline form i of l-malic acid salt of sunitinib
US8916716B2 (en) 2009-11-19 2014-12-23 Ranbaxy Laboratories Limited Process for the preparation of crystalline form II of L-malic acid salt of sunitinib
WO2011092664A1 (en) 2010-01-29 2011-08-04 Ranbaxy Laboratories Limited Crystalline forms of l-malic acid salt of sunitinib
WO2011100325A2 (en) 2010-02-09 2011-08-18 Sicor Inc. Polymorphs of sunitinib salts
CN103833733B (zh) * 2012-11-21 2017-08-25 广东东阳光药业有限公司 一种替尼类药物新晶型
PT3039424T (pt) 2013-08-28 2020-09-03 Crown Bioscience Inc Taicang Assinaturas de expressão genética que permitem prever a resposta de um sujeito a um inibidor multiquinase e métodos de utilização do mesmo
CA2838587A1 (en) 2013-10-18 2015-04-18 Hari Babu Matta Pure crystalline form ii of l-malic acid salt of sunitinib and processes for its preparation
US9278955B2 (en) 2013-10-18 2016-03-08 Sun Pharmaceutical Industries Limited Ascorbic acid salt of sunitinib
CN104693187A (zh) * 2013-12-10 2015-06-10 安杰世纪生物科技（北京）有限公司 一种舒尼替尼L-苹果酸盐晶型λ及其制备方法
CN105085490A (zh) * 2014-05-09 2015-11-25 上海科胜药物研发有限公司 新的舒尼替尼苹果酸盐晶型及其制备方法
WO2020216450A1 (en) 2019-04-25 2020-10-29 Synthon B.V. Pharmaceutical composition comprising amorphous sunitinib
CN115057814A (zh) * 2021-12-07 2022-09-16 山东新时代药业有限公司 一种米力农苹果酸盐晶体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1255752T1 (sl) * 2000-02-15 2007-12-31 Pharmacia & Upjohn Co Llc S pirolom substituirani zaviralci 2-indolinon protein kinaza
GEP20063777B (en) * 2001-08-15 2006-03-27 Upjohn Co Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof

Also Published As

Publication number Publication date
WO2009104021A3 (en) 2009-11-12
AU2009215377A1 (en) 2009-08-27
WO2009104021A2 (en) 2009-08-27
CN101983195A (zh) 2011-03-02
US20110112164A1 (en) 2011-05-12
JP2011512396A (ja) 2011-04-21
EP2252607A2 (en) 2010-11-24

Similar Documents

Publication Publication Date Title
CA2715657A1 (en) Novel polymorphs and processes for their preparation
JP5714824B2 (ja) １−４−（５−シアノインドール−３−イル）ブチル−４−（２−カルバモイルベンゾフラン−５−イル）ピペラジン塩酸塩の多形相
WO2011095059A1 (zh) 达沙替尼多晶型物及其制备方法和药物组合物
RS20060260A (sr) Postupak za dobijanje amino krotonilnih jedinjenja
WO2011086541A1 (en) Novel polymorph of nilotinib monohydrochloride monohydrate
KR20170057441A (ko) Jak 억제제의 바이설페이트의 결정형 및 이의 제조방법
US20110257237A1 (en) Process for the preparation of crystalline forms of sunitinib malate
KR20190035680A (ko) 벨리노스테트의 다형태 및 이의 제조 방법
CA2734965A1 (en) Novel crystalline form and processes for its preparation
CN119613386A (zh) 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法
WO2012098501A1 (en) Febuxostat co-crystals
WO2010027848A2 (en) Forms of lapatinib compounds and processes for the preparation thereof
TW201829420A (zh) [(1S)-1-[(2S,4R,5R)-5-(5-胺基-2-酮基-噻唑并[4,5-d]嘧啶-3-基)-4-羥基-四氫呋喃-2-基]丙基]乙酸酯之新穎固態形式
JP7432503B2 (ja) 塩酸メフパリブの多形体およびその製造方法と使用
CN107033094A (zh) 一种药物共晶的晶型及其制备方法和组合物
WO2009140144A1 (en) Forms of crystalline lapatinib and processes for preparation thereof
US20110263670A1 (en) Novel polymorphs of sunitinib and processes for their preparation
JP6072908B2 (ja) 重水素化ω―ジメチル尿素又はその塩の多形物
JP7618575B2 (ja) Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用
JP2012503641A (ja) アカンプロセートカルシウムの多形体
CN111320596A (zh) 盐酸美呋哌瑞多晶型物及其制备方法
TW202309018A (zh) (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式
WO2024120441A1 (zh) 氧异吲哚-5-甲酰胺类化合物或其盐、溶剂合物的结晶形式或无定形形式
WO2013078973A1 (zh) 一种大粒径达沙替尼及其制备和应用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130828